Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412361 | 0.90 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL4266551 | 0.89 | SMYD2 (0.38) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL15566115 | 0.88 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL23120633 | 0.87 | SMYD2 (0.35) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL4333269 | 0.86 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL12988701 | 0.86 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL5030590 | 0.86 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL31645258 | 0.85 | SMYD2 (0.38) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL13250776 | 0.84 | SMYD2 (0.33) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL706843 | 0.83 | SMYD2 (0.40) | SMYD2SMN1; SMN2CYP3A4HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250241926-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4419207-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025076523-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| CN-118632841-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4419207-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-08 | — | — | US | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| WO-2007064842-A2 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NORTH CAROLINA STATE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1756046-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
| US-6372800-B1 | IMMUNOSUPPRESSIVE EFFECT AND IS USEFUL AS AN INHIBITOR FOR THE REJECTION REACTION OCCURRING IN ORGAN OR BONE MARROW TRANSPLANTATION, AND AS A PREVENTIVE OR REMEDY FOR ARTICULAR RHEUMATISM, ATOPIC ECZEMA (DERMATITIS), BEHCET'S DISEASE, | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0778263-B1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | WELFIDE CORP (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6187821-B1 | SUCH AS 2-AMINO-2-(3-(4-HEPTYLPHENYL)PROPYL)BUTANE-1,4-DIOL; IMMUNOSUPPRESSANT; ADMINISTERING TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND ALLERGIES | WELFIDE CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5948820-A | IMMUNOSUPPRESSANT; PREVENT REJECTION OF ORGAN TRANSPLANT;AUTOIMMUNE DISEASES; MULTIPLE SCLEROSIS; LUPUS; ANTIALLERGENS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0778263-A1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-5574039-A | ANTITUMOR, FUNGICIDES | AGOURON PHARMACEUTICALS, INC. (US) | 1996-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | SMYD2 4207/4885SMN1; SMN2 3728/4885CYP3A4 3780/4885 |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | ARSA, CNKSR1, BCL9L | SMYD2 2835/4885SMN1; SMN2 3345/4885CYP3A4 1102/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | SMYD2 2221/4885SMN1; SMN2 986/4885CYP3A4 4827/4885 |
| US-20250241926-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | SMYD2 1308/4885SMN1; SMN2 2654/4885CYP3A4 35/4885 |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | SMYD2 3255/4885SMN1; SMN2 4090/4885CYP3A4 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.